Antimicrobial Selection for OPRA: Empirical Therapy, Allergy and MCQs

Empirical vs. directed therapy

Empirical therapy is started before (or without) a confirmed causative organism, based on the most likely pathogens for that infection site and setting; directed therapy follows once culture and sensitivity results narrow the choice down. OPRA scenarios that mention a pending or returned culture result are usually testing whether you recognise the point at which empirical therapy should be de-escalated or switched to a narrower agent — not whether you can name every possible pathogen.

Worked examples: empirical choice → directed switch

• Community-acquired pneumonia (mild-moderate, outpatient): empirical amoxicillin (± doxycycline if atypical cover needed) per local Therapeutic Guidelines. Culture grows penicillin-sensitive Streptococcus pneumoniae → continue or de-escalate to narrow-spectrum penicillin; no need to broaden.
• Cellulitis: started empirically per guidelines (typically covering Staphylococcus aureus and Streptococcus species). Wound swab grows methicillin-sensitive S. aureus (MSSA) → switch to flucloxacillin, the narrow-spectrum agent targeted to that organism.
• Suspected urinary sepsis: broad empirical IV cover started pending cultures. Urine culture returns a single organism sensitive to a narrow agent and the patient is afebrile and improving → de-escalate rather than continuing broad cover "to be safe".

Antimicrobial stewardship principles OPRA tests

• Take cultures (blood, urine, wound, sputum as appropriate) before starting antibiotics where this doesn't unduly delay treatment, particularly in sepsis — this is what makes later de-escalation possible.
• Don't prescribe antibiotics for infections that are viral or self-limiting — antibiotic use should be justified by likely bacterial cause, not reflex.
• Use the narrowest-spectrum agent that adequately covers the likely pathogen(s), guided by local/national guidelines (e.g. Therapeutic Guidelines: Antibiotic) — broad-spectrum cover is a deliberate short-term choice, not a default.
• De-escalate once culture and sensitivity results are available, rather than continuing broad empirical cover unnecessarily.
• Review antibiotic necessity daily (or at each ward round) rather than leaving a prescription running unreviewed for its full course by default.
• Match the duration to current guideline-recommended course length — stopping early risks relapse and resistance; running longer than needed does too, without added benefit.
• Review IV therapy at 48–72 hours for an oral switch once the patient is clinically stable and able to tolerate oral intake.

The beta-lactam allergy decision pathway

A reported penicillin allergy is one of the most heavily tested single facts in this topic, because the correct response depends entirely on what the allergy actually was — a vague "penicillin allergy" label in a stem is deliberately incomplete, and OPRA scenarios usually supply (or deliberately withhold) the detail that resolves it.

Reading the allergy history correctly

A patient reporting nausea or diarrhoea on a previous penicillin course does not have a true allergy — that's an intolerance, and penicillins remain an option. A patient reporting a mild, delayed, non-blistering rash has a low-risk allergy history, where a cephalosporin is usually still appropriate given the low cross-reactivity between penicillins and later-generation cephalosporins (driven mainly by side-chain similarity, not the shared beta-lactam ring). A patient reporting anaphylaxis, angioedema, or a severe blistering skin reaction (e.g. Stevens-Johnson syndrome) has a high-risk allergy history. For OPRA purposes, treat this as: avoid beta-lactams (including cephalosporins and carbapenems) and select a non-beta-lactam alternative, unless the scenario explicitly states specialist allergy assessment has cleared a specific agent — real-world practice does allow carefully selected cephalosporins or carbapenems after specialist review in some high-risk patients, but that nuance sits beyond what a single OPRA stem will expect you to reason through.

Sepsis and source control — red flags OPRA scenarios test

• Suspected sepsis: don't delay antibiotics waiting on non-essential investigations — timely empirical therapy takes priority once sepsis is recognised.
• Take blood cultures before the first antibiotic dose where this is feasible without meaningfully delaying treatment — it's what makes later directed therapy possible.
• Look for a source that needs physical intervention, not just antibiotics — e.g. an abscess needs drainage; antibiotics alone won't resolve undrained collections.
• Treat the patient in front of you, not just a culture result in isolation — a colonising organism on a swab doesn't always mean it's the cause of the current clinical picture.

Renal function and monitoring in practice

• Aminoglycosides (e.g. gentamicin) and vancomycin are both renally cleared and nephrotoxic — dose is adjusted to renal function, and levels are monitored (trough for vancomycin, peak/trough for gentamicin) to keep exposure within a therapeutic window.
• Vancomycin also carries an ototoxicity risk, additive with other ototoxic drugs (e.g. aminoglycosides given concurrently).
• Nitrofurantoin: current Australian Therapeutic Guidelines advise avoiding it once renal function is insufficient for the drug to reach effective urinary concentrations — check the current guideline-specified CrCl threshold rather than relying on a fixed number, as thresholds are periodically revised.

Does a penicillin allergy always rule out cephalosporins?

No. Cross-reactivity between penicillins and cephalosporins is much lower than historically assumed and depends mainly on shared side-chain structure. A low-risk allergy history (e.g. a mild, delayed rash) usually still allows a cephalosporin; a high-risk history (anaphylaxis, angioedema, a severe blistering reaction) means beta-lactams should generally be avoided unless a specialist allergy assessment has cleared a specific agent — in real practice, allergy specialists can sometimes still identify a safe cephalosporin or carbapenem for a high-risk patient, but that level of nuance sits beyond a single OPRA exam stem, which will expect the general-avoidance answer unless it explicitly states specialist clearance.

Why is antimicrobial de-escalation tested so often on OPRA?

It's a core antimicrobial stewardship principle with direct patient-safety and public-health consequences — unnecessary broad-spectrum use drives resistance without added clinical benefit once a sensitive, narrower option is identified from culture results.